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Abstract
Background: The overuse of antimicrobials is one of the main factors responsible for the development and
spread of antimicrobial resistance, together with other causes, such as intra- and inter-hospital spread of resistant
microorganisms and infection control policies and practices. The objective of the present study is to report the
trends of Klebsiella pneumoniae and Acinetobacter baumannii antimicrobial resistance indicators in an Italian
intensive care unit (ICU) during a six-year period, from 2008 to 2013.
Methods: Susceptibility data and annual antibiotic consumptions in the ICU were retrospectively obtained from the
clinical laboratory and the pharmacy. Trends over time of resistance rates (RRs) and of incidence densities of
resistant isolates were determined by linear regression.
Results: Isolation density of A. baumannii increased significantly from 2008 (20.4 per 1,000 patient-days) to 2013
(58.1 per 1,000 patient-days) and of K. pneumoniae from 2010 (22.3 per 1,000 patient-days) to 2013 (55.9 per 1,000
patient-days). RRs of third-generation cephalosporins (3GCs)-resistant K. pneumoniae (from 2010: 41.9 %, to 2012:
87.0 %), of carbapenem-resistant K. pneumoniae (from 2008: 0 %, to 2013: 59.2 %), and of carbapenem-resistant A.
baumannii (from 2008: 87.5 %, to 2013: 96.6 %) showed significant increasing trends. Carbapenems was the main
antibiotic class consumed (24.9 % of the total antimicrobial usage density), followed by 3GCs (21.0 %), fluoroquinolones
(20.6 %), aminoglycosides (17.3 %), penicillins (15.1 %) and glycopeptides (1.1 %). Carbapenems consumption
decreased from 2008 to 2012 and then increased in 2013. Glycopeptides consumption decreased from 2008
to 2011 and then increased in 2013. Aminoglycosides consumption decreased from 2008 to 2010 and increased from
2012 to 2013. Finally, 3GC, penicillins and fluoroquinolones consumptions decreased from 2012 to 2013.
Conclusions: RRs of carbapenem-resistant A. baumannii and of carbapenem- and 3GC-resistant K. pneumoniae were
higher than those for Europe. Our findings highlight the necessity to implement an integrated system for monitoring
not only consumption of antibiotics and resistance profiles but also the clonality of alert microorganisms in the ICU for
effective infection control.
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Background
Antimicrobial resistance (AMR) is a severe threat to
public health in Europe and worldwide, leading to
growing costs, treatment failure, and mortality [1, 2].
AMR results in reduced efficacy of drugs, and limits
the available treatment options. The magnitude of the
problem worldwide, the impact of AMR on health
and on costs for the healthcare sector, together with
the societal impact, are still unknown [2]. Thus, surveil-
lance of AMR is considered an essential component of an
effective response to this problem, and results produced
constitute a fundamental source of information on the
burden and trends of resistance [1]. Unfortunately, high
resistance rates (RRs) to antimicrobial agents have
been observed among bacterial pathogens that cause
healthcare-associated and community-acquired infec-
tions worldwide and significant gaps in surveillance,
lack of standards for methodology, data sharing and
coordination have been highlighted [2]. Especially
Gram-negative bacteria, including multidrug resistant
Acinetobacter baumannii and Enterobacteriaceae pro-
ducing Extended-spectrum beta-lactamases (ESBL)
and carbapenemases, have been associated to severe
healthcare-associated infections and their occurrence
has increased in the last decades [1, 3]. In Europe,
the most recent report of the European Antimicro-
bial Resistance Surveillance Network (EARS-Net) de-
scribes a general increase of AMR in the Gram-
negative pathogens including Klebsiella pneumoniae
and A. baumanni [1]. In Italy, the results of the Ital-
ian Nosocomial Infections Surveillance in Intensive
Care Units (SPIN-UTI) network revealed that K.
pneumoniae and A. baumanni are among the most
commonly isolated microorganisms in intensive care
unit (ICU)-acquired infections [4–6].
The overuse of antimicrobials is one of the main fac-
tors responsible for the development and spread of
AMR. Therefore, European countries increasingly imple-
ment actions to control AMR in the community and the
hospital setting through rational use of antimicrobials.
Information on antimicrobial consumption in Europe is
a prerequisite for antibiotic stewardship and can be an
important source for healthcare professionals and policy
makers in order to monitoring progress towards a pru-
dent use of antibiotics [7]. However, other factors, such
as intra- and inter-hospital spread of resistant microor-
ganisms, community contribution to resistance, and
infection control policies and practices, may also play a
role in determining the burden of resistance in a hospital
and should be considered [8]. We have previous
reported intra- and inter-hospital spread of K. pneumo-
niae clones in two Sicilian ICUs [9] and the emergence
of a carbapenem-resistant K. pneumoniae clone in one
of those ICUs [10]. Furthermore, recently, we have
described the dissemination, in the two ICUs of clonally
related isolates of carbapenem-resistant A. baumannii
with simultaneous resistance to colistin, hypothesizing
that prior carbapenem and colistin consumptions may
have acted as triggering factors [11].
All these findings support the need of strict adherence
to control measures to prevent the dissemination of
multidrug-resistant microorganism, together with the
monitoring of antibiotic consumption at local level to
promote the judicious use of antibiotics. The objective
of the present study is to report the trends of K. pneu-
moniae and A. baumannii resistance indicators in an
Italian ICU during a six-year period, from 2008 to 2013.
Methods
Setting
A retrospective study was conducted, during the period
2008–2013, at an 8-bed interdisciplinary ICU of the
Azienda Ospedaliero – Universitaria “Policlinico - Vit-
torio Emanuele” in Catania, Italy. The total number of
patient-days for each year was collected at the unit level.
Microorganisms and antibiotic susceptibility tests
Data on microorganisms isolated from ICU patients
were retrospectively obtained from the clinical labora-
tory of the hospital. Identification and susceptibility
testing, including ESBL test, were performed using the
Phoenix System (Becton Dickinson, Sparks, MD, USA).
A laboratory-based surveillance, without patient-based
data collection, was performed and the susceptibility
data were collected for K. pneumoniae and A. bauman-
nii regardless of whether they were associated with
healthcare-associated or community-acquired infection
or colonization, or whether they were from clinical or
surveillance cultures. Particularly, data on carbapenem
and 3GC -resistant K. pneumoniae and on carbapenem-
resistant A. baumannii were included in the present
study. Isolates were classified as susceptible, intermedi-
ate or resistant according to Clinical and Laboratory
Standards Institute guidelines [12] and, from 2012, to
European Committee on Antimicrobial Susceptibility
Testing guidelines [13]. Copy strains, defined as an
isolate of the same species showing the same susceptibil-
ity pattern throughout a period of 1 month in the same
patient, no matter what the site of isolation, were
excluded [14]. For each species, the isolation density was
calculated as the number of isolates per 1,000 patient-
days. Antibiotic RRs were calculated as the number of
resistant or intermediate isolates divided by the total
number of isolates of the same species tested against the
corresponding antibiotic multiplied by 100. Furthermore,
the incidence density of resistant isolates was calculated
as the number of resistant or intermediate isolates per
1,000 patient-days.
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Antibiotic consumption
Data on annual antibiotic consumption in the ICU,
from 2008 to 2013, were obtained from the pharmacy
of the hospital. Consumption - that is the antimicro-
bial usage density (AD) – was expressed as defined
daily dose (DDD) and was normalized per 1,000
patient-days. The DDD are the standard adult daily
dose of an antimicrobial agent for a 1-day treatment
defined by the World Health Organization [15]. Particu-
larly, data on consumption of third-generation cephalo-
sporins (3GCs: ceftriaxone, cefotaxime and ceftazidime),
penicillins (piperacillin, piperacillin/tazobactam, ampicil-
lin, amoxicillin), glycopeptides (vancomicin), carbapenems
(imipenem, meropenem, and ertapenem), aminoglycosides
(amikacin, gentamicin, tobramicin and netalmicin), and
fluoroquinolones (levofloxacin and ciprofloxacin) were
collected. Notably, gentamicin and ertapenem were intro-
duced into the ICU in 2009 and 2011, respectively.
Statistical analyses
Statistical analyses were performed using the SPSS
22.0 statistical package (SPSS Inc., Chicago, IL, USA).
Trends over time of RRs and of incidence densities of
resistant isolates were determined by linear regression
with the yearly data. Furthermore, rate ratios were
computed to compare ADs between different years.
Pearson’s correlation coefficient (cc) was used to determine
the relationship between antibiotic consumption and anti-
biotic RRs and incidence densities of resistant isolates. A p
value <0.05 was considered statistically significant.
Results
Microorganisms and antibiotic resistance
During the six-year period, among the 5,529 non-
repetitive microbial isolates recovered from clinical or
surveillance samples, Gram-negatives were the most
frequently isolated microorganisms (48.6 %), followed by
fungi (29.6 %) and Gram-positives (21.8 %). Particularly,
a total of 475 K. pneumoniae (8.6 %) and of 463 A. bau-
mannii (8.4 %) were isolated. Isolation density of A.
baumannii increased significantly from 2008 (20.4 per
1,000 patient-days) to 2013 (58.1 per 1,000 patient-
days) and of K. pneumoniae from 2010 (22.3 per 1,000
patient-days) to 2013 (55.9 per 1,000 patient-days)
(Table 1).
Table 1 shows the RRs during the study period. RRs of
3GC-resistant K. pneumoniae (from 2010: 41.9 %, to 2012:
87.0 %), of carbapenem-resistant K. pneumoniae (from
2008: 0 %, to 2013: 59.2 %), and of carbapenem-resistant
A. baumannii (from 2008: 87.5 %, to 2013: 96.6 %) showed
significant increasing trends. Frequencies and incidence
densities (per 1,000 patient-days) of ESBL-producing K.
pneumoniae among 3 GC-resistant K. pneumoniae were
shown in Table 1.
Considering incidence density of resistant isolates (per
1,000 patient-days), significant increasing trends were
reported for 3GC-resistant K. pneumoniae (from 2010 to
2013), carbapenem-resistant K. pneumoniae (from 2008
to 2013), and carbapenem-resistant A. baumannii (from
2008 to 2013) (Table 1).
Antibiotic consumption
Antibiotic consumption over the 6-year period was
7,362 DDD per 1,000 patient-days (AD). Overall car-
bapenems (24.9 % of the total AD) was the main anti-
biotic class consumed, followed by 3GCs (21.0 %),
fluoroquinolones (20.6 %), aminoglycosides (17.3 %),
penicillins (15.1 %) and glycopeptides (1.1 %). Figure 1
shows the heterogeneity of the antibiotic consumption
(in AD), by antibiotic classes, and the time-trend
distribution in the ICU.
In general, the consumption of each antibiotic class
varied with years. Carbapenems consumption decreased
from 2008 to 2012 (rate ratio 0.61; 95 % CI 0.54–0.69)
and then increased, by about 2-fold, in 2013 (rate ratio
1.81; 95 % CI 1.61–2.02). Glycopeptides consumption
decreased from 2008 to 2011 (rate ratio 0.15; 95 % CI
0.06–0.35) and then intensely increased in 2013 (rate
ratio 10.85; 95 % CI 4.73–30.63). Aminoglycosides
consumption decreased from 2008 to 2010 (rate ratio
0.15; 95 % CI 0.12–0.18) whereas it increased from 2012
to 2013 (rate ratio 5.34; 95 % CI 4.27–6.76). Finally,
3GCs (rate ratio 0.51; 95 % CI 0.45–0.58), penicillins
(rate ratio 0.44; 95 % CI 0.37–0.52) and fluoroquinolones
(rate ratio 0.77; 95 % CI 0.67–0.89) consumptions
decreased from 2012 to 2013.
Figure 2 reports trends of incidence density of resist-
ant isolates (per 1,000 patient-days) and of the corre-
sponding antibiotic consumption (in AD) during the
study period. No correlations between the usage of
antimicrobial agents and resistance data were found.
Discussion
Italy is one of the European countries with increasing
spread of antimicrobial-resistant microorganisms, often
multidrug-resistant [1] and with high antibiotic con-
sumption in the hospital setting [1, 7, 16]. Several fac-
tors, such as antimicrobial consumption, clonal spread
of resistant microorganisms, resistance mechanisms that
might differ by species, the human and environmental
reservoir, and infection control strategies, including
screening policies, may play a role in the prevalence of
antimicrobial-resistant pathogens in the hospital setting
[8, 14]. This issue is of interest especially in Italian ICUs
where the highest prevalence of patients on antibiotic
treatment is observed [17] and outbreaks due to
multidrug-resistant K. pneumoniae and A. baumannii
are frequently reported [9–11, 18]. Comparison of our
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data with those of the EARS-Net should be undertaken
with caution, since European results are based on inva-
sive isolates from blood or cerebrospinal fluid, thus not
representative of isolates from other sites [1]. Our study
confirms that carbapenem resistance is endemic for A.
baumannii isolates, with dramatically higher RRs (about
95 %) than those in the other European countries [1].
Furthermore, incidence density of this multidrug-
resistant pathogen increased significantly from 2008 to
2013 in our ICU, and consumption of carbapenems,
after a significant decrease, increased in the last year of
the study. Recently, it has been reported that the in-
creasing use of carbapenems was associated with the
increasing incidence of healthcare-associated infection
due to imipenem-resistant A. baumannii, suggesting that
caution in antibiotic use would play an important role in
managing high RRs [19]. The results of our study, al-
though not confirmatory, may also suggest that increas-
ing carbapenems consumption contributed to increasing
rate of drug-resistant organisms. However, in order to
further explain high RRs of pathogens associated with
infections in the ICUs, it has been suggested [11, 20, 21]
that high RRs are correlated with high rates of antibiotic
use, but increased and/or high RRs may also be due to
transmission between patients. In fact, in the same ICU,
we have recently described the dissemination of clonally
related multidrug-resistant A. baumannii isolates [11].
In Europe, the percentage of carbapenem-resistant K.
pneumoniae is already high and increasing in some coun-
tries. The highest RRs were reported by Greece followed
by Italy (28.8 %) with statistically significant increasing
trends [1]. Since carbapenem- resistant K. pneumoniae
isolates are frequently found to be carbapenemase-
producing, these results highlight and confirm that
surveillance, active screening of patients at high-risk,
notification of health authorities, implementation of
infection control measures and the prudent use of
antimicrobials are key elements to contain the spread
of carbapenem-resistant K. pneumoniae isolates [1, 22, 23].
In Italy since 2013 the Ministry of Health established
a national surveillance of carbapenemase-producing
Enterobacteriaceae (particularly, K. pneumoniae and
Escherichia coli) [24]. In our ICU the percentage of
carbapenem-resistant K. pneumoniae was higher than
that one documented in Europe with a significant
increasing trend, although consumption of carbapen-
ems decreased until 2012 and increased in 2013. As
described for A. baumanni, dissemination of clonally
related carbapenem-resistant K. pneumoniae isolates
has been also previously documented in our unit, thus
Table 1 Isolation density, resistance rates and incidence density of resistant isolates during the period 2008 – 2013
Year
2008 2009 2010 2011 2012 2013 p-value*
Isolation density
(per 1000 patient-days)
Klebsiella pneumoniae 38.0 48.5 22.3 31.9 41.6 55.9 0.497 (0.005,
from 2010 to 2013)
Acinetobacter baumannii 20.4 19.3 29.8 49.0 50.3 58.1 0.002
Resistance rates, %
(number of tested isolates)
3GC-resistant K. pneumoniae 88.7 (53) 69.4 (62) 41.9 (43) 67.2 (64) 87.0 (69) 81.6 (98) 0.806 (0.045
from 2010 to 2012)
ESBL-producing K. pneumoniae
among 3GC-resistant K. pneumoniae
100 100 100 44.2 98.3 93.8 0.674
(39) (42) (18) (43) (59) (80)
Carbapenem-resistant K. pneumoniae 0 (53) 9.7 (62) 2.3 (43) 37.5 (64) 63.8 (69) 59.2 (98) 0.010
Carbapenem resistant A. baumannii 87.5 (14) 95.0 (19) 96.2 (51) 98.9 (92) 93.2 (68) 96.6 (85) 0.021
Incidence density of resistant isolates
(per 1,000 patient-days)
3GC-resistant K. pneumoniae 25.9 25.1 8.9 19.3 32.8 35.5 0.367 (0.027
from 2010 to 13)
ESBL-producing K. pneumoniae
among 3GC-resistant K. pneumoniae
21.5 24.6 8.9 8.5 31.7 33.2 0.436
Carbapenem-resistant K. pneumoniae 0 3.5 0.5 10.8 24.1 25.7 0.009
Carbapenem-resistant A. baumannii 7.7 11.1 25.3 41.3 37.2 37.7 0.014
*Linear regression
Significant values are indicated in bold font
Abbreviation: 3GC third-generation cephalosporin, ESBL Extended-spectrum beta-lactamase
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contributing to the increasing trend of carbapenems
resistance [9, 10]. Notably, results on high carbapenem
RRs of A. baumannii and K. pneumoniae are worrisome
because carbapenems are last-line antibiotics. In addition,
as previously reported, when carbapenems resistance is
due to the presence of carbapenemases, accumulation of
other resistance determinants, makes these isolates
extensively drug- or pandrug-resistant, leaving few or
no effective treatment options [22, 23, 25, 26].
In European countries, a large proportion of 3GC-
resistant K. pneumoniae isolates, ranging between 85 %
and 100 %, was ascertained as ESBL-positive [1]. In our
study, frequencies of ESBL-producing K. pneumoniae
among 3GC-resistant isolates were very high, reaching
100 % in 2008, 2009 and 2010. Furthermore, the inci-
dence density of ESBL producers increased, although
not significantly, from 2010 to 2013. The high percent-
age of ESBL-producing K. pneumoniae complicates the
treatment of serious infections caused by these bacteria
leading to a significant increase in carbapenems use,
considered the first line class for ESBL producer, with a
consequent impact on the emergence of resistance to
these antibiotics [1].
In our ICU the percentage of 3GC-resistant K. pneu-
moniae isolates was higher than that one reported for
Italy (47.7 %) [1]. Furthermore, the incidence density of
resistant isolates increased significantly from 2010 to
2012 together with the 3GC consumption. In 2013, the
3GC consumption decreased but the incidence density
of resistant isolates increased with no evidence of clonal
dissemination of 3GC-resistant K. pneumoniae in the
ICU. Interestingly, in the German ICUs the dramatic
increase of 3GC-resistant K. pneumoniae has been asso-
ciated with an increased trend of antibiotic usage [14].
Finally, in the present study no correlations between
resistance data and the corresponding antibiotic con-
sumption were observed, thus the multifaceted nature of
the spread and emergence of resistance can, at least
partly, explain this result. In fact, although it is clear that
antibiotics may act as promoters of resistance inducing
key processes for the emergence and spread of resist-
ance, as mutagenesis, recombination and/or horizontal
gene transfer [8, 14, 19, 27], this occurrence is also influ-
enced by other factors than by antibiotic consumption
alone. Antibiotic-resistant bacteria, as well as resistance
genes, can spread from person to person to the environ-
ment, and then back to humans thus, infection preven-
tion and control activities to limit the spread of resistant
bacteria are crucial [28].
Furthermore, although DDD measurements are useful
for comparison and benchmarking, they may not fully
correlate with subsequent antibiotic resistance develop-
ment due to the intrinsic biases [29].
Our study has the limitation of the retrospective
study design as well as the fact that is conducted in a
single institution in Italy, thus the results cannot be
representative of all ICUs of Southern Italy. Moreover,
the ecological study design cannot prove a causative
relationship between the two factors. Thus, a prospect-
ive multicentre patient-based study design is needed to
confirm these findings. Furthermore, in our study design,
data on AMR are laboratory-based, thus precluding a
patient-based evaluation (i.e. date of admission to the ICU,
clinical data confirming infection and other information)
2008 2009 2010 2011 2012 2013
Carbapenems 377 290 261 252 231 420
Third-generation cephalosporins 203 281 280 259 343 174
Glycopeptides 20 10 11 3 7 29
Penicillins 170 212 290 110 228 99
Fluoroquinolones 162 400 285 269 227 175




























Fig. 1 Annual consumption of antibiotic classes from 2008 to 2013
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to differentiate whether microorganisms were associated
with healthcare-associated or community-acquired infec-
tion or colonization. Since the emergence of drug-resistant
microorganisms is commonly seen in nosocomial set-
tings and invasive isolates could be of much more inter-
est than microorganisms isolated from colonization
episodes, microorganisms associated with infection epi-
sodes should be analyzed separately. Besides, no data
about other factors such as patient’s characteristics and
the amount of antibiotics prescribed in the outpatient
setting and potential confounders, such as antimicro-
bial stewardship interventions, were taken into account.
Finally, outbreaks not investigated might have influ-
enced resistance data.
Conclusions
The already high percentages and increasing trends of
AMR K. pneumoniae and A. baumannii, described in
this study, illustrate the continuous loss of effective
antimicrobial therapy against these microorganisms
and emphasize the need for comprehensive strategies
targeting prudent use of antibiotics, since treatment
options for infections with multiresistant bacteria are
limited [1]. Besides, since very few effective antibiotics
for multidrug-resistant Gram-negatives pathogens are
likely to be launched in a close future, there is a critical
need to implement strategies against the development of
acquired resistance [30]. In our study, although increasing
trends of AMR organisms and of antibiotic consumption
were described, we did not confirm that increasing anti-
biotic consumption was correlated to increasing RRs,
but we suggest that the introduction of phenotypic and
molecular methods for enhanced surveillance and out-
break detection may result in improved infection control
programs. Our findings also recommend the implementa-
tion of an integrated system for monitoring not only
Fig. 2 Incidence density of resistant isolates and antibiotic consumption during 2008–2013. a. 3GC - resistant K. pneumoniae and 3GC AD.
b. Carbapenem – resistant K. pneumoniae and carbapenem AD. c. Carbapenem – resistant A. baumannii and carbapenem AD. Abbreviation:
3GC, third-generation cephalosporin, AD: antimicrobial usage density; DDD: defined daily dose
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consumption of antibiotics and resistance profiles but also
the clonality of alert microorganisms in the ICU for effect-
ive infection control.
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